Navigation Links
Gilead Announces Achievement of Primary Efficacy Endpoint in Second,Phase III Study of Aztreonam Lysine for Inhalation in Patients With,Cystic Fibrosis

primary objective of the study is to evaluate the safety of repeated exposure to aztreonam lysine for inhalation in people with CF. Each patient's participation in the study will last up to 18 months. Patients will receive treatment with 75 mg of aztreonam lysine for inhalation with the same regimen they received in AIR-CF1 or AIR-CF2 (BID or TID daily).

About Aztreonam Lysine for Inhalation

Aztreonam lysine for inhalation is an antibiotic candidate currently being studied in Phase III clinical trials as a treatment for people with CF who have pulmonary P. aeruginosa. Aztreonam has potent activity against Gram-negative bacteria such as P. aeruginosa. Aztreonam formulated with arginine is a FDA-approved agent for intravenous administration. Aztreonam lysine for inhalation is a proprietary inhaled formulation of aztreonam and has been granted orphan drug designation in the United States and Europe.

About PARI Pharma and the eFlow Electronic Nebulizer

Aztreonam lysine for inhalation is delivered by a novel inhalation device, the eFlow Electronic Nebulizer, developed by PARI Pharma GmbH. eFlow is a quiet, portable nebulizer that enables efficient aerosolization of liquid medications via a vibrating, perforated membrane. PARI Pharma also contributed to the development and optimization of the drug formulation (aztreonam lysine for inhalation) for delivery via eFlow. Based on PARI's 100-year history working with aerosols, PARI Pharma is dedicated to advancing inhalation therapies by developing innovative delivery platforms and new pharmaceutical formulations that work together to improve patient care.

About Cystic Fibrosis

Today, more than 30,000 people in the United States have CF. CF is a chronic, debilitating genetic disease. A major characteristic of CF is production of abnormally thick, sticky mucus in the lungs, trapping bacteria and predisposing patients to lung infections, which continually damage their lungs. Pulmonary in
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
2. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
3. Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
4. Gilead Announces Presentation of Long-Term Data for Ambrisentan, a Potential Treatment for Patients With Pulmonary Arterial Hypertension
5. Gilead Announces Presentation of Positive Phase III Data on Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
6. Data from Preclinical Studies of Gilead Nucleotide Compound GS 9219 to be Presented at AACR
7. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
8. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
10. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
11. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
Post Your Comments:
(Date:7/30/2014)... , July 30, 2014 The Board ... Pharmacy (AMCP) last evening expressed support for the ... Joint Commission of Pharmacy Practitioners (JCPP).  As a ... over a two-year period to develop a scalable, ... "Pharmacists are fast becoming one ...
(Date:7/30/2014)... July 30, 2014  Today the US Surgeon General issued ... sun tanning or sun burns stating they can lead directly ... Boris Lushniak , says that "skin cancer is a ... too much exposure to indoor and outdoor ultraviolet light is ... Aesthetic Medicine, in Boca Raton, Florida , ...
(Date:7/30/2014)... -- Research and Markets has announced the ... Industry Report 2014" report to their offering. ... Global and Chinese Aseptic Packaging Industry Report is a ... the global Aseptic Packaging industry with a focus on ... overview of the industry including definitions, classifications, applications and ...
Breaking Medicine Technology:AMCP Endorses JCPP "Pharmacists' Patient Care Process" 2Indoor and Outdoor Sun Tanning or Sun Burns Directly Linked to Deadly Melanoma Skin Cancer 2Global and Chinese Aseptic Packaging Industry Report 2014 2
... Reportlinker.com announces that a new market ... Commercial Insight: Antihormonal Cancer ... generic sales erosion ... therapies are a class of drugs used ...
... NEW YORK, Nov. 8, 2010 Reportlinker.com ... is available in its catalogue: ... for optimizing growth in key regions and ... The flurry of recent ...
Cached Medicine Technology:Commercial Insight: Antihormonal Cancer Therapies - Leading Brands Strive to Minimize Generic Sales Erosion 2Commercial Insight: Antihormonal Cancer Therapies - Leading Brands Strive to Minimize Generic Sales Erosion 3Commercial Insight: Antihormonal Cancer Therapies - Leading Brands Strive to Minimize Generic Sales Erosion 4Commercial Insight: Antihormonal Cancer Therapies - Leading Brands Strive to Minimize Generic Sales Erosion 5Commercial Insight: Antihormonal Cancer Therapies - Leading Brands Strive to Minimize Generic Sales Erosion 6Commercial Insight: Antihormonal Cancer Therapies - Leading Brands Strive to Minimize Generic Sales Erosion 7Commercial Insight: Antihormonal Cancer Therapies - Leading Brands Strive to Minimize Generic Sales Erosion 8Commercial Insight: Antihormonal Cancer Therapies - Leading Brands Strive to Minimize Generic Sales Erosion 9Opportunities in Emerging Pharma Markets: Strategies for Optimizing Growth in Key Regions and Therapeutic Areas 2Opportunities in Emerging Pharma Markets: Strategies for Optimizing Growth in Key Regions and Therapeutic Areas 3Opportunities in Emerging Pharma Markets: Strategies for Optimizing Growth in Key Regions and Therapeutic Areas 4Opportunities in Emerging Pharma Markets: Strategies for Optimizing Growth in Key Regions and Therapeutic Areas 5Opportunities in Emerging Pharma Markets: Strategies for Optimizing Growth in Key Regions and Therapeutic Areas 6Opportunities in Emerging Pharma Markets: Strategies for Optimizing Growth in Key Regions and Therapeutic Areas 7
(Date:7/31/2014)... CITY, Mo. (PRWEB) July 31, 2014 ... of highly experienced, sub-specialty trained neurosurgeons at the ... of the Spine Program and director of spine surgery. ... in Richland, Wash. , “Dr. Upadhyaya has been recognized ... invasive and complex spine issues. His addition to the ...
(Date:7/31/2014)... Recognizing that today’s medical students are tomorrow’s ... announced today its student discount program. ... a healthcare-related field, as well as medical residents in ... the conference, scheduled for September 17-20, 2014 in San ... , “As a future Registered Dietitian, I’m excited ...
(Date:7/31/2014)... 2014 When it comes to aesthetics ... and improve. As such, Natalie Sharp's Pure Vitality ... for a new, more focused direction and to provide ... patients! , Pure Vitality Rx is Oyster Bay's premier ... wide variety of services primarily dedicated to women. Services ...
(Date:7/31/2014)... (August 1, 2014) While it is known that members ... use alcohol, a new study finds that female enlistees ... than their civilian counterparts. This study was published today ... journal published on behalf of the Inter-University Seminar on ... and Lucky Tedrow studied surveys of nearly 9,000 men ...
(Date:7/31/2014)... July 31, 2014 Sales in the organic ... to 2014, according to radio talk show host Sharon Kleyne, ... rapid growth since 1990. The US economy in the same ... Power of Water radio show, reported this information following a ... a worldwide manufacturer of organic and natural food products. ...
Breaking Medicine News(10 mins):Health News:Saint Luke’s Marion Bloch Neuroscience Institute welcomes Cheerag D. Upadhyaya, M.D., as director of Spine Program 2Health News:Saint Luke’s Marion Bloch Neuroscience Institute welcomes Cheerag D. Upadhyaya, M.D., as director of Spine Program 3Health News:Saint Luke’s Marion Bloch Neuroscience Institute welcomes Cheerag D. Upadhyaya, M.D., as director of Spine Program 4Health News:Student Discounts Offered for International Plant-based Nutrition Healthcare Conference 2Health News:Student Discounts Offered for International Plant-based Nutrition Healthcare Conference 3Health News:Natalie Sharp's Pure Vitality Rx Upgrade - Partnership With Shangri-La Spa and Website Facelift! 2Health News:Women in military less likely to drink than civilian women 2Health News:Organic Food Industry Grew 12% in 2013-2014 Reports Sharon Kleyne Hour Power of Water Host 2Health News:Organic Food Industry Grew 12% in 2013-2014 Reports Sharon Kleyne Hour Power of Water Host 3
... Synovics,Pharmaceuticals, Inc. (OTC Bulletin Board: SYVC), a ... Gange, has been,appointed Principal Executive Officer of ... responsibility of overseeing all executive functions. Mr. ... of directors and is the Chief,Financial Officer ...
... Nationwide,Health Properties, Inc. (NYSE: NHP ) today ... President, Tax. Mr. Laty had previously been the,Vice President, ... had,over eight years experience with a "Big 4" accounting ... Estate Investment Trusts. Mr. Laty is,a graduate of California ...
... do find 11 anti-seizure drugs heighten suicide risk, and ... 10 (HealthDay News) -- Anti-seizure drugs can cause ... warrant the government,s strongest warning label on them, a ... 20-member panel voted unanimously, with one abstention, to back ...
... of Mental Health estimates that in any given year, ... from some form of anxiety disorder, including debilitating conditions ... (PTSD). It is estimated that nearly 15 percent ... PTSD, underscoring the urgency to develop better treatment strategies ...
... trials, design may also mask risk of HIV drug resistance ... study questions whether vaginal microbicides being developed to help protect ... from the virus that causes AIDS. , The study, ... of the National Academy of Sciences , also shows that, ...
... anti-seizure drugs that showed double the risk , , THURSDAY, ... cause increased suicidal tendencies in patients, a U.S. health ... experts voted unanimously to back the findings on 11 ... Administration, the Associated Press reported. , In ...
Cached Medicine News:Health News:Synovics Pharmaceuticals Announces the Appointment of Jyotindra Gange as Principal Executive Officer 2Health News:Synovics Pharmaceuticals Announces the Appointment of Jyotindra Gange as Principal Executive Officer 3Health News:Synovics Pharmaceuticals Announces the Appointment of Jyotindra Gange as Principal Executive Officer 4Health News:Synovics Pharmaceuticals Announces the Appointment of Jyotindra Gange as Principal Executive Officer 5Health News:FDA Advisers Don't Back Epilepsy Drug Warnings 2Health News:Rutgers research identifies brain cells related to fear 2Health News:Rutgers research identifies brain cells related to fear 3Health News:Vaginal Microbicides Might Help More Men Than Women 2Health News:Epilepsy Drugs Can Cause Suicidal Tendencies, FDA Panel Finds 2Health News:Epilepsy Drugs Can Cause Suicidal Tendencies, FDA Panel Finds 3
... As a prophylaxis for deep vein ... effective combination of graduated sequential compression and ... thrombus formation by increasing venous ejection while ... VenaFlow System includes a pump with tube ...
... Full Transportability: Innovative design allows the ... in for therapy or when to ... Choose the prophylactic method to deliver ... both simultaneously. ,Automatic Garment Detection: Automatically ...
... boot specially lasted for fiberglass casts... ... sole for easy ambulation! ,The SlimLine ... last so it fits better than ... with our stretchable upper, a custom ...
The Low Profile boot provides a durable canvas upper, with an open toe and heel. Padded EVA insole protection. The lower outsole compensates for casting thickness. Available in six unisex sizes....
Medicine Products: